[October 17, 2018] |
|
Ferring and Evotec Form Strategic Research Alliance in Reproductive Medicine and Women's Health
Ferring Pharmaceuticals and Evotec AG (Frankfurt Stock Exchange: EVT,
MDAX/TecDAX, ISIN: DE0005664809) today announced a strategic research
alliance to discover and develop new small molecule therapies to treat
patients living with fertility and gynaecological conditions.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20181016005907/en/
Evotec will apply its drug discovery platform to design novel and
efficacious treatments in partnership with Ferring. The multi-target,
multi-year collaboration aims to deliver small molecule pre-clinical
development (PDC) and investigational new drug (IND) ready candidates.
As part of the alliance, Evotec is eligible for undisclosed research
funding and milestones.
"To achieve leadership in reproductive medicine and women's health,
we are expanding beyond our historical expertise in peptides and
tackling molecular targets that are best addressed using small molecule
therapeutics," said Per Falk, Chief Science Officer, Ferring
Pharmaceuticals. "Evotec is a highly regarded company in this field,
and this alliance offers the prospect of significant innovation for
patients. Together, we have the potential to make a difference for both
men and women who are struggling to start a family, and for women
suffering from gynaecological conditions."
"The integration of our industry-leading small molecule discovery and
development platform with Ferring's expertise in reproductive medicine
and women's health will create a powerful combination that we hope will
create a difference for patients suffering from fertility and
gynaecological conditions. We very much look forward to working with
such an innovative partner," commented Dr Mario Polywka, Chief
Operating Officer of Evotec.
About Ferring Pharmaceuticals Ferring Pharmaceuticals is a
research-driven, specialty biopharmaceutical group committed to helping
people around the world build families and live better lives.
Headquartered in Saint-Prex, Switzerland, Ferring is a leader in
reproductive medicine and women's health, and in specialty areas within
gastroenterology and urology. Ferring has been developing treatments for
mothers and babies for over 50 years. Today, over one third of the
company's research and development investment goes towards finding
innovative and personalised healthcare solutions to help mothers and
babies, fro conception to birth. Founded in 1950, Ferring now employs
approximately 6,500 people worldwide, has its own operating subsidiaries
in nearly 60 countries and markets its products in 110 countries.
Learn more at www.ferring.com,
or connect with us on Twitter,
Facebook,
Instagram,
LinkedIn
and YouTube.
About Evotec AG Evotec is a drug discovery alliance and
development partnership company focused on rapidly progressing
innovative product approaches with leading pharmaceutical and
biotechnology companies, academics, patient advocacy groups and venture
capitalists. We operate worldwide and our more than 2,400 employees
provide the highest quality stand-alone and integrated drug discovery
and development solutions. We cover all activities from target-to-clinic
to meet the industry's need for innovation and efficiency in drug
discovery and development (EVT Execute). The Company has established a
unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial
experience and expertise in key therapeutic areas including neuronal
diseases, diabetes and complications of diabetes, pain and inflammation,
oncology, infectious diseases, respiratory diseases and fibrosis. On
this basis, Evotec has built a broad and deep pipeline of approx. 100
co-owned product opportunities at clinical, pre-clinical and discovery
stages (EVT Innovate). Evotec has established multiple long-term
alliances with partners including Bayer, Boehringer Ingelheim, Celgene,
CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others.
For additional information please go to www.evotec.com
and follow us on Twitter (News - Alert) @EvotecAG.
Forward looking statements Information set forth in this
press release contains forward-looking statements, which involve a
number of risks and uncertainties. The forward-looking statements
contained herein represent the judgement of Evotec as of the date of
this press release. Such forward-looking statements are neither promises
nor guarantees, but are subject to a variety of risks and uncertainties,
many of which are beyond our control, and which could cause actual
results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in
events, conditions or circumstances on which any such statement is based.
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20181016005907/en/
[ Back To TMCnet.com's Homepage ]
|